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Vitamin D plays key roles as a natural immune modulator and has been implicated in
the pathophysiology of autoimmune diseases, including systemic lupus erythematosus
(SLE). This review presents a summary and analysis of the recent literature regarding
immunoregulatory effects of vitamin D as well as its importance in SLE development,
clinical severity, and possible effects of supplementation in disease treatment.
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Introduction
1,25-Dihydroxyvitamin D is a steroid hormone, primarily known for its important role in calcium
homeostasis (1). The description that several human tissues and cells express the vitamin D receptor
(VDR), allows a growing interest in extra-skeletal functions of this vitamin (2). It is now clear that
vitamin D plays an essential role in a variety of physiological conditions and that its deficiency is
associated with chronic illnesses, including disorders of calcium metabolism, cancers, cardiovascu-
lar, and of our special interest, autoimmune diseases: applying to both development and severity of
disease (3, 4). In this review, currently available data are summarized to give an overview of the role
vitamin D plays on cells of the immune system and the regulation of inflammatory responses, with
special emphasis on the role it has in the treatment of systemic lupus erythematosus (SLE).
Vitamin D comes from three potential sources: (i) it can be made in the skin from exposure
to sunlight, (ii) nutritional sources, and (iii) supplements (5, 6). In humans, vitamin D is mainly
synthesized in the skin after exposure to UVB whereas only a minor part (<10%) is derived from
dietary sources (7). There are two major forms of vitamin D: ergocalciferol (vitamin D2) that is
obtained from UV irradiation and cholecalciferol (vitamin D3) that is synthesized in the skin and is
present in oil-rich fish (8). Both vitamin D2 and vitamin D3 are used for food fortification (such as
dairy products) and in vitamin D supplements. Vitamin D levels depend on season, reaching their
lowest levels after winter and their maximum at the end of summer.
Vitamin D (D represents D2, or D3, or both) after it is ingested is incorporated into chylomicrons,
which are absorbed into the lymphatic system and enter the venous blood. In the skin, cholecalciferol
is synthesized from 7-dehydrocholesterol when exposed to UVB. Vitamin D that comes from the
skin or diet is biologically inert and requires its first hydroxylation in the liver by the vitamin D-25-
hydroxylase (25-OHase) to 25(OH)D, which represents the main circulating vitamin D metabolite
and is themost reliable parameter to define human vitaminD status (9). However, 25(OH)D requires
a further hydroxylation in the kidneys by the 25(OH)D-1-OHase (CYP27B1) to form the biologically
active form of vitamin D 1,25(OH)2D (9). This process is under strict control of parathyroid
hormone and the phosphaturic hormone fibroblast growth factor 23 (FGF-23). High levels of
vitaminD inhibit CYP27B1 and stimulate CYP24A1, an enzyme thatmetabolizes vitaminD into the
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inactive, water-soluble form, calcitroic acid, which is then excreted
into the bile. Circulating levels of 1,25(OH)2D are determined by
renal CYP27B1 activity. Interestingly, other cell types, including
immune cells, also express CYP27B1, and these cells are able to
convert the inactive hormone into the active form, in an autocrine
or paracrine manner. This process lacks feedback mechanisms (as
the ones described for kidney cells), and allows the production of
high local concentrations of vitamin D.
1,25(OH)2D interacts with VDR, which is present in several
human tissues and cells (1, 9). VDR is a member of transcription
factor family, characterized by a highly conserved DNA-binding
domain and a structurally conserved ligand-binding domain, and
it acts as a modulator of gene transcription (1). 1,25(OH)2D may
be responsible for regulating up to 200 genes that may facilitate
many of the pleiotropic health benefits that have been reported
for vitamin D (1, 5, 6). Ligand binding initiates a conformational
change that increases the receptor’s affinity to the retinoidX recep-
tor (RXR), then VDR-vitamin D complex forms heterodimers
with RXR and the complex binds to vitamin D response elements
on DNA and recruits a number of nuclear co-activator and co-
repressor proteins (10). The gene encoding VDR is located on
chromosome 12q13.11, contains 9 exons and 8 introns and several
single nucleotide polymorphisms (SNPs) have been described.
Mainly four, including BsmI and ApaI (both in intron 8), Fok1
and TaqI (located in the start codon), have been intensively
studied (11).
Serum 25(OH)D is considered as the most accurate marker
for vitamin D. Vitamin D deficiency has been recently recom-
mended by the Institute of Medicine (IOM) as a vitamin D of
<20 ng/mL, whereas vitamin D insufficiency has been defined
as levels between 21 and 29 ng/mL (12, 13). This classifica-
tion is based on vitamin D effects on bone and mineral home-
ostasis. The serum concentration of the active 1,25(OH)2D is
approximately 1000-fold lower and far below the effective con-
centration described in in vitro studies. Most in vitro studies
use more that 100-fold higher concentrations of 1,25(OH)2D
than found in serum, to obtain an effect. It has been suggested
that the level of circulating 1,25(OH)2D is too low to affect
immune responses in vivo, and that sufficient levels are obtained
by local conversion of 25(OH)D3 to 1,25(OH)2D. Other impor-
tant players influencing the bioavailable levels of vitamin D are
the vitamin D-binding protein (DBP) and albumin. 25(OH)D3
and 1,25(OH)2D circulate bound to DBP (85–90%) and albumin
(10–15%)with<1% in their free form (14). Studies inmice lacking
DBP have shown that DBP acts as a vitamin D reservoir by pro-
tecting 25(OH)D3 and 1,25(OH)2D from degradation and renal
secretion (15).
The major cause of vitamin D deficiency is inadequate expo-
sure to sunlight (6, 16). There is an inverse association of serum
vitamin D and body mass index (BMI), and thus, obesity is
also associated with vitamin D deficiency (17). Patients with fat
malabsorption syndromes and bariatric patients are often unable
to absorb the fat-soluble vitamin D, and patients with nephritic
syndrome lose 25(OH)D bound to vitamin DBP in the urine (18).
Patients on a wide variety of medications, chronic granuloma-
forming disorders, some lymphomas, and primary hyperparathy-
roidism have a high risk for vitamin D deficiency (19).
Supplementation with vitamin D in the general population has
shown fracture prevention, suggested benefit in cardiovascular
health, colorectal cancer prevention and reduction of proteinuria
in patients with chronic kidney disease (20, 21). However, a pos-
sible harm of vitamin D supplementation has been documented
in some studies: a meta-analysis showed that supplementation
with calcium and vitamin D could be associated with the modest
increase in the risk of cardiovascular events, especially myocardial
infarction (22). Currently, no international consensus is avail-
able on the optimal vitamin D supplementation level; recom-
mendations differ in many countries and medical societies. The
Endocrine Society considers a supplementation of 10,000 IU daily
to be safe, the IOM considers 4000 IU/day and the European Food
and SafetyAuthority recommends staying below 4000 IU/day. The
most common forms of vitamin D for supplementation are chole-
calciferol (vitamin D3) and ergocalciferol (vitamin D2), although
administration of calcitriol is limited because of potential side
effects. A recent work by Souberbielle et al. (23) has shown that
a target level of at least 30–40 ng/mL of vitamin D serum level was
recommended in adult patients with risk of fractures, falls, can-
cers, and autoimmune and cardiovascular disease. Serum levels
higher than 150 ng/mL may cause acute vitamin D intoxication
with hypercalcemia, hypercalciuria, and calcifications in different
organs.
Vitamin D and the Immune Response
Several studies suggest that calcitriol can enhance the innate
immune response, whereas it can inhibit the adaptive immune
response (24). Early evidence suggesting that vitamin D could act
as stimulant for innate immunity comes from reports about tuber-
culosis treatment with cod liver oil (25). It enhances chemotaxis
and phagocytic capabilities of innate immune cells and activates
the transcription of antimicrobial peptides, such as defensin B
and cathelicidin (26). Low 25(OH)D concentrations have been
linked to increased mortality caused by severe infections in end-
stage renal disease patients, and have been associated with upper
respiratory tract infections and allergic asthma.
In particular, dendritic cells (DCs) are important targets for
the immunomodulatory effects of vitamin D. DCs are profes-
sional antigen presenting cells (APCs) that play an important role
in maintaining peripheral tolerance by preventing self-reactive
T cells from causing autoimmune damage. Through their unique
ability to efficiently capture antigens and trigger the adaptive
immune response, DCs are critical for the defense against infec-
tious agents and tumors (27). In addition to activating immune
responses, DCs also play a central role in peripheral T cell tol-
erance, by inducing T cell anergy or unresponsiveness to self-
antigens (28). Calcitriol and its analogs are able to suppress DC
differentiation (29) and maturation in vitro. Likewise, vitamin D,
by inhibiting the maturation of DCs, can make them tolerogenic
(30–32). It has been shown that DC can produce 1,25(OH)2D
from 25(OH)D in vitro, and respond to this through the VDR in
an autocrine fashion. Since DCs are central to the maintenance
of self-tolerance, it is possible that a deficiency in vitamin D
could have consequences on their maturation and function and
consequently on the risk of developing autoimmune diseases as
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well as disease severity. In addition, vitamin D exerts effects that
oppose the effect of IL-4 on MHC class II antigen expression
in human monocytes and specifically modulates human mono-
cyte phenotype and function by altering HLA-DR expression and
antigen presentation, leaving lytic function intact (33).
T and B cells express VDR and are important target cells of
calcitriol immune regulation. Vitamin D can suppress cellular and
humoral immunity in several animal models as it plays an impor-
tant role in regulating proliferation, differentiation of activated
B cell, and immunoglobulin production (34, 35). In vitro studies
have shown that vitamin D inhibits IL-17 synthesis, inhibiting
Th17 differentiation and increases the quantity of CD4+ CD25+
T regulatory cells, which produce IL-10 and amplifies a Th1–Tr1
switch (36) (Figure 1).
Vitamin D and Autoimmune Diseases
Several studies have now reported vitamin D insufficiencies
in various autoimmune disorders. In addition to observational
studies, numerous randomized trials have addressed the question
whether vitaminD levels are associatedwith the risk of developing
autoimmunity and whether development and disease progression
can be influenced by vitamin D supplementation. In the following
section, we have summarized the latest results associating vita-
min D insufficiency and vitamin D supplementation in SLE. If
causal, these associations might be of great importance for public
health.
Vitamin D and Systemic Lupus Erythematosus
Systemic lupus erythematosus is a chronic multisystem autoim-
mune disease that can manifest with a diverse array of clini-
cal symptoms and which is characterized by the production of
autoantibodies directed against nuclear antigens (37). Systemic
injury may arise as a consequence of inflammation caused by
direct autoantibody-mediated tissue injury and the deposition of
complement-fixing immune complexes (ICs) (38). IC-mediated
inflammation has been shown to damage multiple organs, such
as skin, joints, kidneys, brain, and blood vessels. Cellular and
molecular mechanisms underlying this autoimmune disease are
not completely understood. Currently, there is no cure for SLE,
and treatments, such as long-term corticosteroids, may contribute
to further health risks.
In SLE animal models, it has been shown a relation between
vitamin D and disease manifestations. Lemire et al. (39) showed
that in the MRL/1 SLE mouse model, supplementation with
25(OH)D for 18weeks reduced dermatologic lesions, proteinuria,
and anti-DNA antibodies. Instead, Vaisberg et al. (40) described
opposing results in the NZB/W mice that were injected with
different concentrations of vitamin D. Treatment with cholecal-
ciferol led to a worsening of the histopathological findings in the
kidneys of female F1 NZB/Wmice. In vitro studies of SLE-derived
PBMCs have shown that when these cells are incubated with cal-
citriol, reduced cellular proliferation and anti-DNA antibodies are
observed (41). Also, in vitro vitamin D reduced the expression of
CD40, MHC class II, CD86, and inhibited the activation of APCs
FIGURE 1 | Vitamin D effects on the innate and adaptive immune response. Vitamin D has been shown to enhance chemotaxis, antimicrobial peptides, and
macrophage differentiation. It can also inhibit DCs maturation, Th1 and Th17 differentiation, and promotes immunoregulatory functions of Treg cells.
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Subjects Intervention (type, dose, duration) Study results
Petri, 2013,
USA (64)
1006 SLE Oral cholecalciferol 50,000 IU weekly+ 200U
calcium/vitamin D twice daily
A 20-U increase in the 25(OH)D level was associated with








Lower VitD correlates with higher disease activity
Change in 25(OH)D after 12months is associated with
improvement in inflammatory-hemostatic markers
Ruiz-Irastorza, 2010,
Spain (70)
80 SLE Oral cholecalciferol 600–800 IU day for 24months Beneficial effect on fatigue, no significant correlations were
seen in SLEDAI or SDI values
Lima, 2015, Brazil 60 juvSLE Oral cholecalciferol 50,000 IU/week or placebo for
24weeks
Beneficial effect on fatigue and decrease disease activity
Aranow, 2015,
USA (73)




34 SLE Oral cholecalciferol Intensive regimen significantly raise vitamin D serum levels
Intensive R: 300,000 IU initial bolus followed by
50,000 IU monthly (850,000 annually)
No significant differences in disease activity, or SLE
serology were found
Standard R: 25,000 IU monthly (300,000 annually) for
12months and then switched in the second year
Piantoni, 2015,
Italy (74)
34 SLE Oral cholecalciferol Vitamin D treatment promotes regulatory T cells
proliferation and production of Th2 cytokinesIntensive R: 300,000 IU initial bolus followed by
50,000 IU monthly (850,000 annually)
Standard R: 25,000 IU monthly (300,000 annually) for
12months and then switched in the second year
Terrier, 2012,
France (75)
20 SLE Oral cholecalciferol Increase of naive CD4 T cells
100,000 IU/week during 4weeks Increase in regulatory T cells
100,000 IU/month for 6months Decrease Th1 and Th17 cells
Decrease memory B cells
Decrease anti-DNA antibodies
derived from SLE patients (42). Ben-Zvi et al. (43) showed that
vitamin D treatment reduced the expression of IFNα-regulated
genes in healthy and SLE patients-derived DCs in response to
factors in activating SLE plasma.
Levels ofmicroRNA (miRNA)-146a in PBMCs correlate signif-
icantly with disease activity in SLE patients and urinary expres-
sion correlates with estimated glomerular filtration rate (44).
Recent studies have shown that after treatment with vitamin D,
miRNA-146a levels of SLE patients tend to decrease (44).
Association studies with VDR polymorphism and SLE suscep-
tibility have been performed in different populations with contro-
versial results (45–47). A meta-analysis study, including a total of
11 case-control studies (8 from Asian, 2 European, 1 Latino pop-
ulation), of 1683 patients and 1883 healthy individuals revealed
associations between the VDR polymorphisms and SLE (48).
These findings show that the BsmI and FokI polymorphisms are
associated with increased risk of SLE, especially in the Asian
population. Limitations to the study are the low representation of
European and Latino populations.
Hypovitaminosis D is highly prevalent in SLE as a result of
avoidance of sunshine, renal insufficiency, and the use of medica-
tions, such as glucocorticoids, anticonvulsants, and antimalarials,
which alter the metabolism of vitamin D, vitamin D-binding pro-
tein levels or downregulate the functions of the VDR (49, 50). Sev-
eral studies have reported suboptimal vitamin D levels in patients
with SLE, whose prevalence described varies between 36.8% and
75% in the different populations studied (49, 51–54). Low levels
of vitamin D have been correlated with disease activity, and are
associated with osteoporosis, fatigue, and certain cardiovascular
risk factors in SLE patients (49, 55). The wide variation reported
can be related to age, ethnicity, geographic location, and season at
the time of the study.
Vitamin D Deficiency and Disease Activity
There are several cross-sectional studies examining the relation-
ship between low vitamin D levels and SLE activity. It has been
shown that vitamin D deficiency has an association with disease
activity and some clinical manifestations, but there are discrep-
ancies between the different populations studied. No associations
between adolescent dietary vitamin D intake and adult SLE risk
were observed in a prospective cohort of women (56, 57). Mok
et al. reported in a cross-sectional study with 290 Chinese patients
with SLE, that vitamin D deficiency was inversely correlated
with disease activity, measured by SLEDAI scores (58), and in
another study, they reported associations with anti-dsDNA levels
(59). In addition, Lertratanakul et al. showed that lower baseline
vitamin D levels are associated with higher cardiovascular risk
factors and more active SLE (60). Besides, SLE patients with
higher vitamin D levels were less likely to have hypertension and
hyperlipidemia. A recent study that evaluated 129 Indian patients
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with SLE found a negative correlation of vitamin D levels with
disease activity, anti-dsDNA, plasma IFN-α, and IFN-α gene
expression (61). Baseline vitamin D levels were not associated
with relapse-free survival rate (62). In Australian patients, Yap
et al. showed that low vitamin D is associated with higher disease
activity, and an increase in vitamin Dwas associated with reduced
disease activity over time (50). Other studies have shown that
vitamin D deficiency is associated with a higher B cell activation,
more frequent leukopenia or renal involvement with proteinuria,
and higher titers of anti-DNA (51, 63–66). By contrast, others
studies have reported no association between vitamin D and
fatigue, SLEDAI score or cytokine profile (67–69).
Overall, both in vitro and in vivo studies of vitamin D effects in
SLE provide immunological basis for potential beneficial effects
of vitamin D in this disease. Despite all this overwhelming evi-
dence favoring the use of vitamin D in SLE, to date, vitamin D
supplementation is not the standard of care for patients with SLE.
Interventional studies have been reported (see Table 1), with the
purpose of changing clinical outcomes; however, results are still
not conclusive.
Ruiz-Irastorza et al. showed no significant correlations with
SLE clinical activity, evaluating SLEDAI or SDI values, and sug-
gested that increasing vitamin D levels may have a beneficial
effect on fatigue (70). Petri et al. studied a prospective cohort of
1006 patients receiving supplementation with 50,000 IU weekly
for 128weeks. Results showed that vitamin D increases were
associated with a decrease in disease activity and proteinuria
(64). Also, Abou-Raya et al. reported that lower vitamin D levels
correlated with disease activity and improvement in inflamma-
tory and hemostatic parameters was observed after 12months
treatment (71). Latest studies have found no association between
supplementation and disease activity and no changes in IFN sig-
nature in vitamin D deficient SLE patients (72, 73). Other studies
have shown effects in cytokine profiles and T cell differentia-
tion (74, 75).
A recent systematic review and meta-analyses of observational
and randomized trials (76) found no convincing evidence of a
clear role of vitamin D with highly significant results in both
randomized and observational studies. The number of random-
ized, controlled trials with vitamin D is scarce, so more data
are needed to reach a conclusion. Also, the effects of multiple
compounds when administered simultaneously, and the follow-
up time, may be inadequate to allow differences in disease occur-
rence. More efforts are required in order to clarify the role that
vitamin D has in this disease, to regulate the type of supplemen-
tation required, and to determine the minimal beneficial levels.
Specific attention to maintaining optimal vitamin D levels may be
beneficial in the management of SLE.
Conclusion
Vitamin D exerts important regulatory functions on cells from
the innate as well as from the adaptive immune response. Indeed,
accumulating evidence has shown that insufficient vitamin D
levels may lead to dysregulation of immune responses, and thus
contribute to autoimmune diseases. There is no consensus about
recommended targeted serum levels and the optimal mode and
dose of vitamin D supplementation. It seems that higher doses for
supplementation could have better outcomes in disease activity,
but still there is great variability between studies and no con-
clusions can be obtained. More and larger studies are needed to
determine how vitaminD supplementation affects the pathophys-
iology of SLE and how itmay contribute to better efficacy of actual
therapies.
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